Literature DB >> 8499773

The role of complement-derived chemotactic factors in lung injury induced by preformed immune complexes.

M Tanoue1, Y Yoshizawa, T Sato, H Yano, Y Kimula, K Miyamoto.   

Abstract

Our previous studies have suggested a role for complement fragments presumably activated by immune complexes in patients with hypersensitivity pneumonitis. The present study has shown that circulating complement depletion by cobra venom factor resulted in the reduction in severity of immune-complex-mediated pulmonary inflammation. The activity of chemotactic factors for neutrophils generated in bronchoalveolar lavage fluids in complement-depleted animals was significantly diminished to 61.2% compared to the undepleted animals. In addition, reduced activity of chemotactic factors resulted in a marked reduction of accumulation of neutrophils in bronchoalveolar lavage fluids indicating that chemotactic factors play an important role in the sequestration of neutrophils on the alveolar side of the lung. In conclusion, chemotactic factors in bronchoalveolar lavage fluids which preceded the accumulation of polymorphonuclear cells are partially derived from complement.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8499773     DOI: 10.1159/000236497

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  3 in total

1.  Neutrophilic granulocytes are the predominant cell type infiltrating pancreatic islets in contact with ABO-compatible blood.

Authors:  L Moberg; O Korsgren; B Nilsson
Journal:  Clin Exp Immunol       Date:  2005-10       Impact factor: 4.330

2.  Complement depletion aggravates Staphylococcus aureus septicaemia and septic arthritis.

Authors:  E Sakiniene; T Bremell; A Tarkowski
Journal:  Clin Exp Immunol       Date:  1999-01       Impact factor: 4.330

3.  Interferon-gamma is necessary for the expression of hypersensitivity pneumonitis.

Authors:  G Gudmundsson; G W Hunninghake
Journal:  J Clin Invest       Date:  1997-05-15       Impact factor: 14.808

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.